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One mechanism through which trinucleotide repeat
expansions cause disease is RNA-mediated toxicity. Gener-
ally, this is thought to involve sequestration of RNA-
binding proteins and the resulting generation of secondary
effects on the expression of other genes. Yu et al. speculate
on a different mechanism by which this toxicity might
occur, through the production of anti-sense transcripts of
the repeat. This appears to lead to the generation of
repeat-derived siRNAs that are toxic. In aDrosophilamodel,
they found a synergistic effect to the toxicity of CTG and
CAG repeats. This effect depends on the action of Dcr2
and Ago2, which are needed for siRNA biogenesis, and
leads to the downregulation of other CAG-containing
genes. Thus, although the end result is the same as in
previous models in that secondary changes in expression
to other genes are central to the RNA-mediated pathogen-
esis, the process by which this occurs is different. Are the
models mutually exclusive? Perhaps not, meaning that
the consequences of expansion of a simple 3 base pair
repeat might not be so simple after all.
Yu et al. (2011). PLOS Genet. 7, e1001340.
Enhancing the Human Genome Sequence
Despite the fact that we know the individual stretches of
sequence that make up the human genome, we can’t
read it like a novel from chromosome 1 down through
chromosome Y because we don’t yet understand all of
the instructions held within those sequences. In a massive
study that was part of the ENCODE project, Ernst et al.
used chromatin profiling to systematically identify regula-
tory elements across the genome. They performed chro-
matin immunoprecipitation followed by high-throughput
sequencing (ChIP-seq) for nine chromatin marks across
nine different cell types. This allowed them to distinguish
six broad classes of chromatin states that they could then
correlate with functional data, such as gene expression,
transcription-factor recognition, and sequence-motif
enrichments, in order to link enhancer elements with their
target genes and predict additional regulatory interactions.
The authors went one further step through analysis of
a large number of intergenic SNPs that had previously
been associated with various complex traits. They found
that these SNPs are enriched in strong enhancer elements,
and several either created or disrupted a regulatory
element. Because the earlier analyses linked enhancers1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Amewith their target genes, this highlights several genes of
potential functional significance in complex disease.
Ernst et al. (2011). Nature. Published online March 23,
2011. 10.1038/nature09906.
Pharmacogenetic Testing Informs Carbamazepine
Prescription
Doctors prescribe drugs to alleviate patient suffering; the
last thing they want is for the drug itself to do harm. Unfor-
tunately, for the drug carbamazepine, which is one of the
most widely prescribed drugs for the treatment of epilepsy
(as well as other disorders), drug-induced hypersensitivity
reactions occur in 5%–10% of treated individuals. This
can be as severe as the potentially fatal Stevens-Johnson
syndrome and toxic epidermal necrolysis (SJS-TEN), which
are characterized by high fever and a rapidly developing
blistering rash. In Asians, the HLA B*1502 allele in the
major histocompatibility (MHC) complex is known to
confer risk for SJS-TEN. Chen et al. used this knowledge
to design a prospective pharmacogenetic study in Taiwan.
In their study, individuals who possessed this allele were
advised to use an alternativemedication to carbamazepine.
In contrast to the expected ten cases of SJS-TEN in their
sample of more than 4000 patients, no cases of SJS-TEN
were diagnosed in their study, which strongly argues that
genotyping should be performed prior to carbamazepine
administration in HanChinese individuals. Unfortunately,
this does not hold true in all populations; for example, the
same allele is not correlated with carbamazepine hypersen-
sitivity in European populations. Thus, McCormack et al.
performed a combination of genetic association studies
to identify hypersensitivity risk alleles in European popula-
tions. They uncovered HLA A*3101, which is correlated
with the full range of hypersensitivity reactions to carba-
mazepine and appears to alter risk predictions for reactions
to carbamazepine, but probably not as much as does HLA
B*1502 in Asians. A prospective study similar to the one
by Chen et al. is needed to determine the utility of pharma-
cogenetic testing in European populations.
Chen et al. (2011). New Eng. J. Med. 364, 1126–1133.
McCormack et al. (2011). New Eng. J. Med. 364, 1134–
1143.
Flash in the Pan
I went to high school in the ‘80s when Debbie Gibson hit
the scene, and all girls in my school wore Debbie-inspiredta, GA 30322, USA
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leggings and a ponytail on the side of their heads; teen
social selection favored the emulation of the latest pop
icon. This reminds me of the flash in the pan that is the
dark morph of the peppered moth, that textbook example
of natural selection. The dark morph, which became
highly advantageous during the Industrial Revolution
before pollution controls were enacted, spread across
Britain. Just as one woman was the source of some classic
80s fashions, van’t Hof et al. recently found that a single
moth was the source of the dark coloring in the British
moth population, demonstrating the power of natural
selection. They based this finding on haplotype analysis
and linkage disequilibrium measurements in British
moth populations. Perhaps unfortunately for the dark
moths, environmental initiatives made this once hugely
successful moth morph fade into relative obscurity in the
moth population, and the lighter colored morph again
predominates—kind of like the teens nowadays have
moved on to other pop icons to determine their fashion
‘‘morphs.’’
van’t Hof et al. (2011). Science. Published online March 14,
2011. 10.1126/science.1203043.
GWAS Identifies a Schizophrenia Risk Gene
Although association studies are somewhat passe´ now that
whole-exome sequencing is becoming the rage, they still
have some secrets to reveal. A recent association analysis522 The American Journal of Human Genetics 88, 521–522, May 13,by Vacic et al. for copy-number variation (CNV) identified
overexpression of a single gene as contributing to schizo-
phrenia risk in some individuals. Vacic et al. figured that
most of the large, recurrent CNVs that are due to nonallelic
homologous recombination have been found, so they
would look for enrichment for overlapping events as
a way to tie together small, rare events and identify new
genomic regions that contribute to schizophrenia. After
undertaking a preliminary study to identify regions of
interest, they performed an association study by using
a binning strategy in a separate case-control sample. This
approach implicated microduplications of chromosome
7q36.3 in schizophrenia, and a separate sample provided
preliminary evidence that these duplications might also
contribute to autism. Although not found in a large
number of people with schizophrenia, microduplications
in this region were ten times more common in cases
than in controls, and they all overlapped or lay close to
VIPR2, highlighting the contribution of a single gene in
this region. Duplications are associated with increased
VIPR2 mRNA levels and response to stimulation of the
encoded G-protein-coupled receptor (VPAC2), suggesting
that the duplications are associated with increased activity
of this pathway. Because selective VPAC2 inhibitors have
already been identified, this opens the door to modulating
this pathway to examine the effect on schizophrenia.
Vacic et al. (2011). Nature 471, 499–503This Month in Our Sister JournalsAnother FMR1-Related Disorder?
Mitochondrial dysfunction and oxidative stress are
believed to be key components to the pathogenesis of
Parkinsonism. Recent work by Loesch et al. suggests that
certain alleles at the FMR1 CGG repeat might feed into
this pathway and contribute to the pathogenesis in some
individuals. Because FMR1 premutation alleles cause
a tremor and ataxia syndrome, some groups have sought
evidence that these alleles are associated with Parkin-
sonism. This group’s previous study reported an excess of
FMR1 premutation and gray-zone alleles—those just under
the premutation size—in a group of people on the Parkin-
son disease (PD) spectrum. They are now tackling the
molecular underpinnings for this association and found
that FMR1 CGG repeat size and its sense and antisensetranscript levels correlate with measures of disease severity
in patients with PD and FMR1 premutation or gray-zone
alleles. Coincident with these effects are elevations in the
level of cytochrome C1 mRNA and depletions of mito-
chondrial DNA. Elevations of cytochrome C1 transcripts
are also found in PD patients who lack premutation or
gray-zone alleles, but to a lesser extent than those seen
with the larger repeat sizes, leading the authors to specu-
late that the toxic effects of these FMR1 alleles synergize
with the pathogenic process that leads to Parkinsonism.
Given that approximately one in 30 individuals is esti-
mated to carry a gray-zone allele at FMR1, this synergy
could have a substantial effect on PD if it proves true.
Loesch et al. (2011). Genet. Med. Published online April 15,
2011. 10.1097/GIM0b013e3182064362.2011
